2247544-02-9

Basic information

• Product Name: 2-(5-((2-((4-chlorobenzyl)thio)-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)thio)-1H-tetrazol-1-yl)-N,N-dimethylethan-1-amine hydrochloride
• CAS NO: 2247544-02-9
• Molecular Weight: 498.463
• Mol File: 2247544-02-9.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 2-(5-((2-((4-chlorobenzyl)thio)-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)thio)-1H-tetrazol-1-yl)-N,N-dimethylethan-1-amine hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(5-((2-((4-chlorobenzyl)thio)-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)thio)-1H-tetrazol-1-yl)-N,N-dimethylethan-1-amine hydrochloride(2247544-02-9)
• EPA Substance Registry System: 2-(5-((2-((4-chlorobenzyl)thio)-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)thio)-1H-tetrazol-1-yl)-N,N-dimethylethan-1-amine hydrochloride(2247544-02-9)

Safety Data

• Hazardous Substances Data: 2247544-02-9(Hazardous Substances Data)

Usage

Molecular Structure

The compound has a complex structure consisting of a tetrazole ring, a triazolopyrimidine ring, and a dimethylethanamine group.

Functional Groups

The compound contains a thiol group (-SH), a chlorobenzyl group (C6H4Cl-), and a dimethylamino group (-N(CH3)2).

Pharmaceutical Applications

Due to its intricate structure and potential pharmaceutical properties, the compound is likely used in pharmacological research and drug development.

Solubility

The addition of the hydrochloride salt (HCl) enhances the compound's solubility in aqueous solutions, making it more suitable for certain applications in the pharmaceutical industry.

Upstream product

• 41266-78-8 5-((4-chlorobenzyl)thio)-4H-1,2,4-triazol-3-amine 
• 61607-68-9 1-[2-(dimethylamino)ethyl]-1,2-dihydro-5H-tetrazole-5-thione 
• 104-83-6 1-Chloro-4-(chloromethyl)benzene 

Relevant articles and documents

Development of Highly Potent, Selective, and Cellular Active Triazolo[1,5- a]pyrimidine-Based Inhibitors Targeting the DCN1-UBC12 Protein-Protein Interaction

The cullin-RING ubiquitin ligases (CRLs) are responsible for about 20% of cellular protein degradation and regulate diverse cellular processes, and the dysfunction of CRLs is implicated in human diseases. Targeting the CRLs has become an emerging strategy for the treatment of human diseases. Herein, we describe the discovery of a hit compound from our in-house library and further structure-based optimizations, which have enabled the identification of new triazolo[1,5-a]pyrimidine-based inhibitors targeting the DCN1-UBC12 interaction. Compound WS-383 blocks the DCN1-UBC12 interaction (IC50 = 11 nM) reversibly and shows selectivity over selected kinases. WS-383 exhibits cellular target engagement to DCN1 in MGC-803 cells. WS-383 inhibits Cul3/1 neddylation selectively over other cullins and also induces accumulation of p21, p27, and NRF2. Collectively, targeting the DCN1-UBC12 interaction would be a viable strategy for selective neddylation inhibition of Cul3/1 and may be of therapeutic potential for disease treatment in which Cul3/1 is dysregulated.